Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ATYRNASDAQ:BGMNASDAQ:CALTNASDAQ:OCUL On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeATYRAtyr PHARMA$3.67+5.0%$3.25$1.42▼$4.66$325.31M0.79920,005 shs462,396 shsBGMQilian International Holding Group$12.78+3.5%$10.97$5.26▼$14.78$1.24B1.3326,329 shs9,300 shsCALTCalliditas Therapeutics AB (publ)$40.00$40.00$15.25▼$43.00$1.19B1.7710,339 shsN/AOCULOcular Therapeutix$7.37-3.1%$7.38$4.79▼$11.77$1.17B1.511.41 million shs164,506 shs20 Stocks to Sell NowToday, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceATYRAtyr PHARMA+1.45%+5.44%+12.58%-17.88%+348,999,900.00%BGMQilian International Holding Group+1.48%+8.61%+10.74%+21.35%+1,235,999,900.00%CALTCalliditas Therapeutics AB (publ)0.00%0.00%0.00%0.00%+81.82%OCULOcular Therapeutix+1.20%+8.57%+3.97%+2.98%+20.83%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationATYRAtyr PHARMA2.8482 of 5 stars3.61.00.00.03.83.30.6BGMQilian International Holding GroupN/AN/AN/AN/AN/AN/AN/AN/ACALTCalliditas Therapeutics AB (publ)N/AN/AN/AN/AN/AN/AN/AN/AOCULOcular Therapeutix4.2938 of 5 stars3.43.00.04.14.32.50.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceATYRAtyr PHARMA 3.14Buy$18.60432.95% UpsideBGMQilian International Holding Group 0.00N/AN/AN/ACALTCalliditas Therapeutics AB (publ) 2.00Hold$39.25-1.88% DownsideOCULOcular Therapeutix 2.88Moderate Buy$16.25113.82% UpsideCurrent Analyst Ratings BreakdownLatest ATYR, BGM, OCUL, and CALT Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/19/2025ATYRAtyr PHARMAHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$35.00 ➝ $35.005/6/2025OCULOcular TherapeutixNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$15.00 ➝ $14.004/8/2025OCULOcular TherapeutixWilliam BlairSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform4/8/2025OCULOcular TherapeutixNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$15.00 ➝ $15.003/18/2025OCULOcular TherapeutixRoyal Bank of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform$17.003/14/2025ATYRAtyr PHARMAHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$35.00 ➝ $35.003/11/2025OCULOcular TherapeutixNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$15.003/4/2025OCULOcular TherapeutixJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price Target$19.003/4/2025OCULOcular TherapeutixHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$15.00 ➝ $15.00(Data available from 5/21/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookATYRAtyr PHARMA$235K1,321.80N/AN/A$1.54 per share2.27BGMQilian International Holding Group$25.10M47.88N/AN/A$6.10 per share2.03CALTCalliditas Therapeutics AB (publ)$1.60B0.74N/AN/A$1.06 per share37.74OCULOcular Therapeutix$59.65M20.30N/AN/A$0.79 per share9.62Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateATYRAtyr PHARMA-$50.39M-$0.81N/AN/AN/AN/A-79.44%-59.16%N/ABGMQilian International Holding Group-$1.44MN/A0.00∞N/AN/AN/AN/AN/ACALTCalliditas Therapeutics AB (publ)-$43.96M-$1.85N/A8.68N/A-30.18%-212.04%-27.96%N/AOCULOcular Therapeutix-$80.74M-$1.15N/AN/AN/A-283.74%-45.18%-30.87%8/6/2025 (Estimated)Latest ATYR, BGM, OCUL, and CALT EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/7/2025Q1 2025ATYRAtyr PHARMA-$0.19-$0.17+$0.02-$0.17N/AN/A3/13/2025Q4 2024ATYRAtyr PHARMA-$0.23-$0.18+$0.05-$0.18$0.02 millionN/A3/3/2025Q4 2024OCULOcular Therapeutix-$0.24-$0.29-$0.05-$0.29$16.89 million$17.08 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthATYRAtyr PHARMAN/AN/AN/AN/AN/ABGMQilian International Holding GroupN/AN/AN/AN/AN/ACALTCalliditas Therapeutics AB (publ)N/AN/AN/AN/AN/AOCULOcular TherapeutixN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioATYRAtyr PHARMA0.025.415.41BGMQilian International Holding GroupN/A3.392.82CALTCalliditas Therapeutics AB (publ)9.442.692.59OCULOcular Therapeutix0.1913.0112.94Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipATYRAtyr PHARMA61.72%BGMQilian International Holding GroupN/ACALTCalliditas Therapeutics AB (publ)2.83%OCULOcular Therapeutix59.21%Insider OwnershipCompanyInsider OwnershipATYRAtyr PHARMA3.70%BGMQilian International Holding Group58.66%CALTCalliditas Therapeutics AB (publ)2.20%OCULOcular Therapeutix2.30%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableATYRAtyr PHARMA5389.00 million80.84 millionOptionableBGMQilian International Holding Group29897.22 million2.48 millionN/ACALTCalliditas Therapeutics AB (publ)18029.79 million29.14 millionOptionableOCULOcular Therapeutix230159.30 million151.71 millionOptionableATYR, BGM, OCUL, and CALT HeadlinesRecent News About These CompaniesGraham Capital Management L.P. Takes $321,000 Position in Ocular Therapeutix, Inc. (NASDAQ:OCUL)May 20 at 4:21 AM | marketbeat.comOcular Therapeutix, Inc. (NASDAQ:OCUL) Shares Bought by Second Line Capital LLCMay 19 at 6:45 AM | marketbeat.comOcular Therapeutix, Inc. (NASDAQ:OCUL) Shares Bought by Point72 Asset Management L.P.May 19 at 5:53 AM | marketbeat.comOcular Therapeutix, Inc. (NASDAQ:OCUL) Holdings Boosted by Northern Trust CorpMay 19 at 3:17 AM | marketbeat.comPolar Asset Management Partners Inc. Trims Holdings in Ocular Therapeutix, Inc. (NASDAQ:OCUL)May 18 at 6:08 AM | marketbeat.comBalyasny Asset Management L.P. Acquires New Shares in Ocular Therapeutix, Inc. (NASDAQ:OCUL)May 17, 2025 | marketbeat.comPatient Square Capital LP Raises Stake in Ocular Therapeutix, Inc. (NASDAQ:OCUL)May 16, 2025 | marketbeat.comOcular Therapeutix, Inc. (NASDAQ:OCUL) Stock Holdings Boosted by OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLCMay 15, 2025 | marketbeat.comRichard L. Md Lindstrom Purchases 10,000 Shares of Ocular Therapeutix, Inc. (NASDAQ:OCUL) StockMay 14, 2025 | marketbeat.comOcular Therapeutix™ to Participate in Upcoming Investor ConferencesMay 14, 2025 | globenewswire.comOcular Therapeutix, Inc. (NASDAQ:OCUL) Director Richard L. Md Lindstrom Acquires 10,000 SharesMay 13, 2025 | insidertrades.comHC Wainwright Expects Weaker Earnings for Ocular TherapeutixMay 10, 2025 | marketbeat.comWilliam Blair Cuts Earnings Estimates for Ocular TherapeutixMay 10, 2025 | marketbeat.comWhat is HC Wainwright's Forecast for OCUL FY2026 Earnings?May 9, 2025 | marketbeat.comDeep Track Capital LP Grows Stock Position in Ocular Therapeutix, Inc. (NASDAQ:OCUL)May 9, 2025 | marketbeat.comAnalyst Expectations For Ocular Therapeutix's FutureMay 8, 2025 | nasdaq.comOcular Therapeutix (NASDAQ:OCUL) Trading Down 6.5% on Analyst DowngradeMay 8, 2025 | marketbeat.comOcular Therapeutix (NASDAQ:OCUL) Price Target Cut to $14.00 by Analysts at Needham & Company LLCMay 8, 2025 | marketbeat.com212,944 Shares in Ocular Therapeutix, Inc. (NASDAQ:OCUL) Acquired by First Trust Advisors LPMay 8, 2025 | marketbeat.comOcular Therapeutix (NASDAQ:OCUL) Shares Gap Down - What's Next?May 7, 2025 | marketbeat.comVIDEO: OTX-TKI reduces intraretinal fluid over 1 year with single injectionMay 7, 2025 | healio.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeATYR, BGM, OCUL, and CALT Company DescriptionsAtyr PHARMA NASDAQ:ATYR$3.66 +0.18 (+5.01%) As of 11:37 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.aTyr Pharma, Inc. engages in the discovery and development of medicines based on novel biological pathways. Its product pipeline includes ATYR1923, ATYR2810, NRP2 mAbs, and AARS-1, DARS-1. The company was founded by Paul Schimmel, Xiang-Lei Yang and Bruce Beutler on September 8, 2005 and is headquartered in San Diego, CA.Qilian International Holding Group NASDAQ:BGM$12.78 +0.43 (+3.48%) As of 11:36 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Qilian International Holding Group Limited manufactures and distributes active pharmaceutical ingredients (APIs), traditional Chinese medicine derivatives (TCMD), and other by-products in China. The company provides licorice products, including Gan Di Xin, an antitussive and expectorant medicine; Qilian Shan Licorice Extract, an ingredient for pharmaceutical companies to manufacture traditional licorice tablets; and Qilian Shan licorice liquid extract, a primary ingredient for medical preparation companies to produce compound licorice oral solutions. It offers Qilian Shan oxytetracycline tablets to prevent and treat a range of diseases in chickens, turkeys, cattle, swine, and human; and Qilian Shan oxytetracycline APIs for pharmaceutical companies to manufacture medications. In addition, the company offers TCMD products, such as Ahan antibacterial paste to treat refractory chronic skin diseases; heparin products, including heparin sodium preparations for pharmaceutical companies to produce medications for cardiovascular diseases, cerebrovascular diseases, and hemodialysis; and Zhu Xiaochang sausage casings, which are natural food products for culinary application. Further, it provides Xiongguan organic fertilizers to improve crop yield and soil's chemical properties and reduce soil compaction; and Xiongguan organic-inorganic compound fertilizers to increased plant growth. Qilian International Holding Group Limited was incorporated in 2019 and is based in Jiuquan, the People's Republic of China.Calliditas Therapeutics AB (publ) NASDAQ:CALT$40.00 0.00 (0.00%) As of 05/19/2025Calliditas Therapeutics AB (publ), a commercial-stage bio-pharmaceutical company, focused on identifying, developing, and commercializing novel treatments in orphan indications with an initial focus on renal and hepatic diseases with significant unmet medical needs in the United States, Europe, and Asia. It offers Nefecon (TARPEYO/Kinpeygo), an oral formulation of budesonide to reduce the loss of kidney function in adults with immunoglobulin A nephropathy. The company's lead compound is Setanaxib, a NOX inhibitor that is in Phase 2b clinical trial for the treatment of primary biliary cholangitis; and in Phase 2 clinical trial for the treatment of squamous cell carcinoma of the head and neck cancer and idiopathic pulmonary fibrosis, as well as for solid tumors and Alport Syndrome. Calliditas Therapeutics AB (publ) was incorporated in 2004 and is headquartered in Stockholm, Sweden.Ocular Therapeutix NASDAQ:OCUL$7.36 -0.24 (-3.09%) As of 11:37 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Ocular Therapeutix, Inc., a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis. It is developing AXPAXLI, an axitinib intravitreal implant that is in phase 3 trials for the treatment of wet age-related macular degeneration and other retinal diseases; PAXTRAVA, a travoprost intracameral implant, which is in phase 2 clinical trials for the treatment of open-angle glaucoma or ocular hypertension; OTX-CSI, a cyclosporine intracanalicular insert that has completed phase 2 clinical trials for the treatment of dry eye disease; and OTX-DED, a dexamethasone intracanalicular insert, which is in phase 2 clinical trials for the short-term treatment of the signs and symptoms of dry eye disease. In addition, the company offers modulator for intermediate and late dry age-related macular degeneration; and gene delivery for inherited retinal degenerations and protein biofactory indications. The company has a strategic collaboration with Regeneron Pharmaceuticals, Inc. (Regeneron) for the development and commercialization of products using the company's sustained-release hydrogel in combination with Regeneron's large molecule VEGF-targeting compounds for the treatment of retinal diseases; and AffaMed Therapeutics Limited for the development and commercialization of DEXTENZA and OTX-TIC. Ocular Therapeutix, Inc. was incorporated in 2006 and is headquartered in Bedford, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Rivian Stock Below $20: Charging Up or in the Breakdown Lane? Viking Holdings Posts Strong Q1, Eyes Growth Ahead 2 Reasons Netflix’s 40% Rally Is Far From Over Qualcomm’s Re-Entry Into the CPU Market May Not Be Enough Applied Digital's Strategic AI Play Gains Momentum Hims & Hers Stock Chart Points to Strong Bullish Continuation Boeing Landed New Deals With China and the Saudis for More Upside CrowdStrike’s Rally Faces a Test—Here’s Why That’s Good Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
